Recent advances in the treatment of multiple sclerosis

References

• SetoSCarreraCJKubotaMWassonDBCarsonDAMechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytesJ Clin Invest19857523773832579098
   PubMed Web of Science ®Google Scholar
• LassmannHLucchinettiCFCortical demyelination in CNS inflammatory demyelinating diseasesNeurology200870533233318227414
   PubMed Web of Science ®Google Scholar
• DaviesGRRamio-TorrentaLHadjiprocopisAEvidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosisJ Neurol Neurosurg Psychiatry2004757998100215201359
   PubMed Web of Science ®Google Scholar
• SpurgeonSYuMPhillipsJDEpnerEMCladribine: not just another purine analogue?Expert Opin Investig Drugs200918811691181
   PubMed Web of Science ®Google Scholar
• SeronoEClinicalTrials.govCLARITY A phase III, randomized, double-blind, three-arm, placebo-controlled, multi-center study to evaluated the safety and efficacy of oral cladribine in subjects with relapsing-remitting multiple sclerosis2009 Available from: http://clinicaltrials.gov/ct2/show/nct00213135Accessed 2010 Aug 20
   Google Scholar
• HavrdovaEGalettaSHutchinsonMEffect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) studyLancet Neurol20098325426019201654
   PubMed Web of Science ®Google Scholar
• GeaGiovannoniSafety and tolerability of cladribine tablets in relapsing-remitting multiple sclerosis during the 96-week, phase III, double-blind, placebo-controlled CLARITY studyPresentation at ECTRIMS 2009Dusseldorf, Germany2009
   Google Scholar
• MehlingMBrinkmannVAntelJFTY720 therapy exerts differential effects on T cell subsets in multiple sclerosisNeurology200871161261126718852441
   PubMed Web of Science ®Google Scholar
• BrinkmannVFTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous systemBr J Pharmacol200915851173118219814729
   PubMed Web of Science ®Google Scholar
• BrinkmannVWiltCKristoficCFTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effectsTransplant Proc2001337–83078308011750323
   PubMed Web of Science ®Google Scholar
• PinschewerDDOchsenbeinAFOdermattBBrinkmannVHengartnerHZinkernagelRMFTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memoryJ Immunol2000164115761577010820254
   PubMed Web of Science ®Google Scholar
• MironVELudwinSKDarlingtonPJFingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slicesAm J Pathol201017662682269420413685
   PubMed Web of Science ®Google Scholar
• ColesAJCompstonDASelmajKWAlemtuzumab vs interferon beta-1a in early multiple sclerosisN Engl J Med2008359171786180118946064
   PubMed Web of Science ®Google Scholar
• HauserSLWaubantEArnoldDLB-cell depletion with rituximab in relapsing-remitting multiple sclerosisN Engl J Med2008358767668818272891
   PubMed Web of Science ®Google Scholar
• YangJSXuLYXiaoBGHedlundGLinkHLaquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis ratsJ Neuroimmunol20041561–23915465591
   PubMed Web of Science ®Google Scholar
• ComiGPulizziARovarisMEffect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLancet200837196302085209218572078
   PubMed Web of Science ®Google Scholar
• Teva Pharmaceutical IndustriesA multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-301 Study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis NCT00988052
   Google Scholar
• de JongRBezemerACZomerdijkTPvan de Pouw-KraanTOttenhoffTHNibberingPHSelective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarateEur J Immunol1996269206720748814248
   PubMed Web of Science ®Google Scholar
• WierinckxABreveJMercierDSchultzbergMDrukarchBvan damAMDetoxication enzyme inducers modify cytokine production in rat mixed glial cellsJ Neuroimmunol20051661–213214315993952
   PubMed Web of Science ®Google Scholar
• SchimrigkSBruneNHellwigKOral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot studyEur J Neurol200613660461016796584
   PubMed Web of Science ®Google Scholar
• BiogenIdecClinicalTrials.govA randomized, multicenter, placebo-controlled and active reference (glatiramer acetate) comparison study to evaluate the efficacy and safety of BG00012 in subjects with relapsing-remitting multiple sclerosis (CONFIRM)2010 Available from: http://clinicaltrials.gov/ct2/show/nct00451451Accessed 2010 Aug 20
   Google Scholar
• BiogenIdecClinicalTrials.govA randomized, multicenter, double-blind, placebo-controlled, dose-camparison study to determine the efficacy and safety of BG00012 in subjects with relaping-remitting multiple sclerosis (DEFINE)2010 Available from: http://clinicaltrials.gov/ct2/show/nct00420212Accessed 2010 Aug 20
   Google Scholar
• GlaxoSmithKlinehttp://ClinicalTrials.govRandomised, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the MRI efficacy and the safety of six months administration of SB-683699 in subjects with relapsing-remitting multiple sclerosis (MS)2008 Available from: http://clinicaltrials.gov/ct2/show/nct00395317Accessed 2010 Aug 20
   Google Scholar
• KornTMagnusTToykaKJungSModulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide – mechanisms independent of pyrimidine depletionJ Leukoc Biol200476595096015328336
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventishttp://ClinicalTrials.govLong-term extension of the multinational, double-blind, placebo controlled study EFC6049 (HMR1726D/3001) to document the safety of two doses of teriflunomide (7 and 14 mg) in patients with multiple sclerosis with relapses2010 Available from: http://clinicaltrials.gov/ct2/show/nct00803049Accessed 2010 Aug 20
   Google Scholar
• Sanofi-Aventishttp://ClinicalTrials.govA randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with glatiramer acetate in subjects with multiple sclerosis2009 Available from: http://clinicaltrials.gov/ct2/show/nct00475865Accessed 2010 Aug 20
   Google Scholar
• Sanofi-Aventishttp://ClinicalTrials.govA randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with interferon-beta in subjects with multiple sclerosis2010 Available from: http://clinicaltrials.gov/ct2/show/nct00489489Accessed 2010 Aug 20
   Google Scholar
• Sanofi-Aventishttp://ClinicalTrials.govAn international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 14 mg once daily versus placebo in patients with a first clinical episode suggestive of multiple sclerosis2010 Available from: http://clinicaltrials.gov/ct2/show/nct00622700Accessed 2010 Aug 20
   Google Scholar
• Genzyme/Bayerhttp://ClinicalTrials.govComparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One (CARE-MS I)2010 Available from: http://clinicaltrials.gov/ct2/show/nct00530348Accessed 2010 Aug 20
   Google Scholar
• Genzyme/Bayerhttp://ClinicalTrials.govComparison of Alemtuzumab and Rebif^® Efficacy in Multiple Sclerosis, Study Two (CARE-MS II)2010 Available from: http://clinicaltrials.gov/ct2/show/nct00548405Accessed 2010 Aug 20
   Google Scholar
• HawkerKO’ConnorPFreedmanMSRituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trialAnn Neurol200966446047119847908
   PubMed Web of Science ®Google Scholar
• Genentech H-LRhttp://ClinicalTrials.govA study of the efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis2010 Available from: http://clinicaltrials.gov/ct2/show/nct00676715Accessed 2010 Aug 20
   Google Scholar
• BielekovaBCatalfamoMReichert-ScrivnerSRegulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosisProc Natl Acad Sci U S A2006103155941594616585503
   PubMed Web of Science ®Google Scholar
• BielekovaBRichertNHowardTHumanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon betaProc Natl Acad Sci U S A2004101238705870815161974
   PubMed Web of Science ®Google Scholar
• BielekovaBHowardTPackerANEffect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosisArch Neurol200966448348919364933
   PubMed Web of Science ®Google Scholar
• VigliettaVBourcierKBuckleGJCTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trialNeurology2008711291792418794494
   PubMed Web of Science ®Google Scholar
• AxtellRCde JongBABonifaceKT helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitisNat Med201016440641220348925
   PubMed Web of Science ®Google Scholar